Umeclidinium Bromide and Vilanterol Trifenatate
Bronchodilator & Anti-asthma Preps: Inhalants · Antimuscarinic/Beta-2 agonist
Indications
Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Not indicated for the relief of acute bronchospasm or for the treatment of asthma.
Dosage
Adults: 1 inhalation once daily by the orally inhaled route only, should be taken at the same time every day.
Adverse Effects
Pharyngitis, sinusitis, lower RTI, constipation, diarrhoea, pain in extremity, muscle spasms, neck pain and chest pain.
Risk Factor (Pregnancy/Lactation)
Contraindications: Asthma. Acute episodes of bronchospasm or acutely deteriorating COPD. Precautions: CV disease (e.g. cardiac insufficiency, arrhythmias, hypertension), diabetes mellitus, narrow-angle glaucoma, hypokalaemia, prostatic hyperplasia/bladder neck obstruction, seizure disorders, thyrotoxicosis. Pregnancy. Lactation.
Interactions
Long-acting Beta2-agonists. Diuretics. Anticholinergics. MAOIs. Tricyclic antidepressants. Strong CYP450 3A4 inhibitors (e.g. Ketoconazole).
Advice to Patient
Contact prescriber if you experience any of these symptoms: Palpitations, chest pain, rapid heart rate, tremor, nervousness, eye pain/discomfort, blurred vision, visual halos, coloured images in association with red eyes from conjunctival congestion and corneal edema, difficulty passing urine, painful urination etc.
Pharmacokinetics
Absorption: Rapidly absorbed via lungs. Bioavailability: Umeclidinium: Absolute: Approx. 13%. Vilanterol: Absolute: Approx. 27%. Metabolism: Umeclidinium: Hepatic. Vilanterol: Undergoes extensive first-pass metabolism in the liver. Half-life elimination, plasma: Umeclidinium: 11 hrs. Vilanterol: Approx. 11 hrs. Time to peak, plasma: 5-15 mins. Excretion: Umeclidinium: Mainly via faeces (92%). Urine (<1%). Vilanterol: Mainly via urine (70%). Faeces (30%).
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.